Financial Performance - The company achieved a main business revenue of 2,645.07 million RMB in 2023, representing a growth of 25.11% compared to the previous year[6]. - The company's operating revenue for 2023 reached approximately CNY 2.65 billion, representing a 24.59% increase compared to CNY 2.13 billion in 2022[57]. - Net profit attributable to shareholders for 2023 was approximately CNY 416.12 million, a significant increase of 130.58% from CNY 180.47 million in 2022[57]. - The net profit attributable to shareholders of the listed company increased by 130.58% to 416.12 million yuan, while the net profit excluding non-recurring gains and losses rose by 141.52% to 383.41 million yuan[109]. - The net cash flow from operating activities increased by 174.30% to approximately CNY 634.45 million, driven by substantial growth in revenue and operating profit[59]. - The company's total assets at the end of 2023 were approximately CNY 7.11 billion, reflecting a 3.09% increase from CNY 6.89 billion at the end of 2022[57]. - The net assets attributable to shareholders increased by 2.46% to approximately CNY 5.65 billion at the end of 2023[57]. - The company's basic earnings per share increased by 134.62% to CNY 2.44 in 2023, compared to CNY 1.04 in 2022[85]. Research and Development - The company has invested a total of 7,033.32 million RMB in various R&D projects, with a cumulative investment of 25,963.14 million RMB[11]. - The R&D team consists of 366 personnel, accounting for 16.96% of the total workforce, with an average salary of 33.04 thousand yuan[18]. - The company has established multiple R&D platforms, including a national-level enterprise technology center and a national postdoctoral research station, enhancing its research capabilities[21]. - Research and development expenses amounted to CNY 220,098,300, representing a 20.81% increase from the previous year, accounting for 8.29% of total revenue[82]. - The company is actively increasing R&D investment to develop new technologies and products, focusing on core technology transformation[184]. Product Development and Innovation - The company is conducting clinical trials for several new products, including a new type of artificial lens and a high-permeability scleral lens, with expected product approvals in early 2024[11]. - The company is developing innovative products such as a new type of cross-linked chitosan gel and a long-acting cross-linked sodium hyaluronate injection, which are expected to enhance treatment efficacy[11]. - The company successfully launched a new hydrophobic aspheric intraocular lens product in June 2023, with several other innovative products in various stages of clinical trials[82]. - The company has developed a second-generation PRL product for myopia correction, with clinical trials progressing smoothly, and high-permeability scleral lenses expected to complete registration testing by February 2024[157]. - The company has developed a large-scale sodium hyaluronate injection product that is now in the clinical application stage[191]. Market Expansion and Strategy - The company has expanded its international presence through acquisitions, focusing on transferring advanced technologies and products to the domestic market[1]. - The company plans to continue its market expansion and product development strategies, focusing on high-margin products like hyaluronic acid[3]. - The company aims to enhance the brand image of its high-end hyaluronic acid product "Haimi" and expand market penetration in 2024[127]. - The company is focusing on expanding its product matrix across four major categories: hyaluronic acid, epidermal repair gene engineering preparations, RF, and laser equipment, catering to diverse consumer needs in medical and home beauty applications[160]. - The company plans to focus on the ophthalmology sector in 2024, adapting to changes in industry policies and leveraging its multi-brand product line advantages[126]. Operational Efficiency and Cost Management - The company has reduced cash outflow from investment activities due to effective cash management, particularly in the purchase of bank certificates[5]. - The company emphasized the importance of cash flow management, noting efforts to reduce accounts receivable and enhance collection efforts[59]. - The company has established a procurement center to enhance operational efficiency and reduce costs through centralized purchasing of raw materials and equipment[178]. - The company is actively monitoring overdue accounts receivable and has reduced or stopped credit sales to clients with credit risks, leading to a decrease in accounts receivable balance[4]. Market Position and Brand Influence - The company's ophthalmic viscoelastic product has maintained a market share of 16 consecutive years as the leading product in the domestic market[16]. - The company has a leading brand influence in various treatment areas, with its products ranking among the top in sales within their respective categories[27]. - The company is the only domestic manufacturer with a full range of orthopedic sodium hyaluronate injection products in 2ml, 2.5ml, and 3ml specifications[17]. - The company holds a 46.45% market share in the orthopedic joint cavity viscoelastic supplement market in China, maintaining the leading position for nine consecutive years[172]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.90% in 2022, also maintaining this position for 16 years[183]. Challenges and Future Outlook - The company has not yet achieved profitability since its listing, as indicated in the report[44]. - The management highlighted future growth strategies, although specific commitments were not made to investors[60]. - The group plans to advance the registration of several key products in 2024, including hydrophobic aspheric multifocal intraocular lenses and innovative intraocular filling biological gel products[142]. - The group aims to enhance its operational efficiency and core competitiveness through the integration of acquired companies and resource allocation in 2024[153]. - The Chinese medical aesthetics market is projected to grow at a compound annual growth rate of 15%-20% over the next five years, driven by increasing consumer demand and a low penetration rate compared to other countries[132].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 645,995,271.22, representing a year-on-year increase of 5.68%[6] - The net profit attributable to shareholders for Q1 2024 was CNY 97,541,532.98, reflecting a growth of 20.16% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,217,851.02, which is an increase of 33.05% year-on-year[6] - The basic earnings per share for Q1 2024 was CNY 0.58, up by 23.40% from CNY 0.47 in Q1 2023[18] - Net profit for the current period reached 92,488,777.12, an increase from 84,951,683.69 in the previous period, representing a growth of approximately 6.4%[41] - Total revenue from operating profit was 114,427,839.61, slightly up from 111,265,909.95, indicating a growth of about 1.9%[41] - The company's earnings per share attributable to shareholders increased to 97,541,532.98 from 81,177,581.15, representing a growth of about 20.2%[41] Assets and Liabilities - The total assets at the end of Q1 2024 amounted to CNY 7,192,952,822.94, a 1.23% increase from the end of the previous year[26] - As of March 31, 2024, total current assets amounted to approximately RMB 3.75 billion, slightly down from RMB 3.75 billion at the end of 2023[32] - The company’s total assets reached approximately RMB 7.19 billion, up from RMB 7.11 billion at the end of 2023[32] - The company's total liabilities amounted to 1,070,720,682.01, a decrease from 1,088,203,977.97, reflecting a reduction of approximately 1.6%[45] - The total equity attributable to shareholders increased to 5,755,069,480.72 from 5,650,064,203.23, marking an increase of about 1.9%[45] Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY 75,969,702.64, a decrease of 4.96% compared to the previous year[6] - The company reported a net cash inflow from investment activities of CNY 159,290,447.77 for Q1 2024, compared to CNY 156,184,009.96 in the same period last year[19] - The company reported a net cash inflow from financing activities of approximately RMB 42.14 million, a significant improvement from a net outflow of RMB 20.94 million in the previous period[38] Research and Development - The total R&D expenditure for Q1 2024 was CNY 64,900,123.30, which accounted for 10.05% of the operating revenue, an increase of 1.28 percentage points year-on-year[26] Shareholder Information - The top ten shareholders hold a combined 88.68% of the shares, with the largest shareholder owning 28.17%[28] Government Subsidies - The company received government subsidies amounting to CNY 3,820,341.64 during the reporting period[26] - Government subsidies received during the reporting period decreased significantly compared to the same period last year, leading to a 75.83% decline in non-recurring net gains[28] Inventory and Cash Management - Cash and cash equivalents at the end of the reporting period were RMB 846.19 million, an increase from RMB 772.22 million at the end of the previous year[38] - Inventory as of March 31, 2024, was approximately RMB 533.64 million, showing a slight increase from RMB 526.17 million at the end of 2023[32] Strategic Focus - The company continues to focus on high-margin hyaluronic acid products, contributing to overall gross profit growth[28] - The company is actively exploring new product development and market expansion strategies to enhance its competitive position[28] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 1.72%, an increase of 0.24 percentage points year-on-year[26] - Interest income decreased to 17,894,671.58 from 19,194,643.89, a decline of approximately 6.8%[41] - Other comprehensive income after tax showed a significant drop to -21,216,593.79 from 3,063,929.44, indicating a negative shift[41] - The company reported a decrease in credit impairment losses to -476,413.55 from -2,445,931.34, showing an improvement in credit quality[41] - The company’s capital reserve decreased to 2,903,610,489.65 from 2,980,937,753.79, a decline of approximately 2.6%[45]

Financial Performance - Total revenue for 2023 reached RMB 2,634,910,000, an increase of 25.2% compared to RMB 2,103,438,000 in 2022[6] - Net profit attributable to shareholders was RMB 416,121,000, up 130.5% from RMB 180,470,000 in the previous year[6] - Earnings per share increased to RMB 2.44 in 2023, compared to RMB 1.04 in 2022[6] - The company achieved a total revenue of RMB 2,634.91 million in 2023, representing a year-on-year increase of 25.27%[7] - The company’s net profit attributable to ordinary shareholders was approximately RMB 416.12 million, an increase of about RMB 235.65 million or 130.58% from RMB 180.47 million in 2022[42] - The overall gross margin for the company was 70.34% in 2023, up from 68.79% in 2022, primarily due to strong sales performance of high-margin hyaluronic acid products[37] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 7,105,497,000, a rise from RMB 6,892,399,000 in 2022[6] - Total liabilities increased to RMB 1,088,204,000 from RMB 990,016,000 in 2022, resulting in a debt-to-asset ratio of 15.3%[6] - Total current liabilities of the group as of December 31, 2023, were approximately RMB 715.95 million, an increase of about RMB 204.67 million or 40.03% compared to December 31, 2022[43] - The total liabilities of the group as of December 31, 2023, were approximately RMB 1,088.20 million, with a debt-to-asset ratio of 15.31%, an increase of 0.95 percentage points from 14.36% as of December 31, 2022[48] Research and Development - Research and development efforts are focused on innovative technologies to enhance product offerings and competitiveness[6] - Research and development expenses amounted to RMB 220.10 million, an increase of 20.81% year-on-year, accounting for 8.35% of total revenue[11] - The company is actively developing innovative high-end artificial lens products, with several clinical trials underway for new technologies[18] - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with several innovative products entering the registration phase[11] Market Expansion and Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[6] - Management remains optimistic about future performance, expecting continued revenue growth and improved profitability[6] - The company is exploring potential mergers and acquisitions to accelerate growth and market expansion[6] - The company aims to expand its market share in the medical aesthetics sector by promoting its differentiated hyaluronic acid products through a broad sales network in 2024[36] Product Performance - The ophthalmic product line generated revenue of RMB 924.65 million, accounting for 35.10% of total revenue, with a growth rate of 20.72%[10] - The medical beauty and wound care product line saw revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a year-on-year growth of 41.44%[10] - The company's hyaluronic acid product line includes three generations, with the first generation achieving sales of RMB 599.41 million, accounting for 56.94% of total revenue in 2023, reflecting a growth of 95.78% year-on-year[23] - The company's ophthalmic products achieved revenue of RMB 924.65 million, an increase of approximately RMB 158.68 million, representing a growth rate of 20.72% compared to the previous year[14] Shareholder Returns - The board proposed a final dividend of RMB 1.00 per share for the year 2023, reflecting a 150% increase compared to the previous year[7] - The company plans to distribute a final dividend of RMB 1.00 per share for the year ending December 31, 2023, totaling RMB 167,360,375.00[58] - The company’s profit distribution policy emphasizes a stable and sustainable return to investors, with cash dividends prioritized when conditions allow[64] Corporate Governance - The company has established a corporate governance structure to protect shareholder rights and enhance accountability[123] - The company has adhered to all applicable provisions of the corporate governance code during the reporting period[117] - The board consists of 11 members, including 4 executive directors, 2 non-executive directors, and 5 independent non-executive directors[123] - The company has established internal policies to ensure the board receives independent views and opinions, with independent non-executive directors entitled to seek independent professional advice at the company's expense[127] Risk Management - The company has established a stable and effective risk management mechanism, including an internal audit system and risk assessment management system[183] - The company faces potential risks from intensified market competition, which could impact its market share and profitability[157] - Regulatory changes in China's healthcare system may increase compliance costs and reduce product demand if the company fails to adapt[158] Employee and Management - The total employee compensation for the group during the reporting period was approximately RMB 630.08 million, with a total workforce of 2,158 employees[44] - The company has implemented a restricted stock incentive plan approved on March 7, 2022, to attract and retain core management and technical personnel, with a total of 1,800,000 shares granted under this plan[91] - The company has arranged appropriate liability insurance for its directors, supervisors, and senior management[84] Community and Social Responsibility - The company made donations amounting to RMB 100,000 during the reporting period[119] - Community engagement includes donations, public welfare activities, and industry meetings[200] Compliance and Legal Matters - The company has not encountered any corruption or bribery lawsuits during the reporting period, reflecting its commitment to integrity and compliance[186] - The company has complied with all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules regarding related party transactions[116]

识别风险，发现价值 请务必阅读末页的免责声明 1 / 4 [Table_PageText] 昊海生科|年报点评 [Table_FinanceDetail] 资产负债表 单位：百万元 现金流量表 单位：百万元 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 至 12 月 31 日 2022A 2023A 2024E 2025E 2026E 流动资产 3,532 3,750 4,079 4,878 5,799 经营活动现金流 231 634 214 1,322 1,011 货币资金 2,545 2,741 2,372 3,170 3,747 净利润 190 412 558 758 908 应收及预付 440 380 940 804 960 折旧摊销 204 198 178 195 205 存货 485 526 675 791 958 营运资金变动 -138 90 -658 362 -177 其他流动资产 62 103 92 112 134 其它 -26 -66 136 7 74 非流动资产 3,360 3,355 3,398 3,569 3,569 投资活动现金流 -682 - ...

[Table_Main] 证券研究报告 | 公司点评 昊海生科(688366.SH) 2024 年 03 月 10 日 增持（维持） 所属行业：医药生物/医疗器械 当前价格(元)：104.22 证券分析师 赵雅楠 资格编号：S0120523070002 邮箱：zhaoyn＠tebon.com.cn 易丁依 资格编号：S0120523070004 邮箱：yidy＠tebon.com.cn 市场表现 -17% -9% 0% 9% 17% 26% 昊海生科 沪深300 -26% | --- | --- | --- | --- | |--------------------------------|----------------|--------------|-------| | -34% 2023-03 \n沪深 300 对比 | 2023-07 \n1M | 2023-11 \n2M | 3M | | 绝对涨幅 (%) | -3.50 | 3.87 | -3.10 | | 相对涨幅 (%) | -8.85 | -3.80 | -7.37 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 1.《昊 ...

Financial Performance - The company reported a basic earnings per share of CNY 2.44 for 2023, a 134.62% increase compared to CNY 1.04 in 2022[24]. - The diluted earnings per share also stood at CNY 2.44, reflecting the same 134.62% growth year-over-year[24]. - The net profit attributable to shareholders was CNY 416,000,000, which represents 40.09% of the total profit allocated for cash dividends[9]. - The company's operating revenue for 2023 reached approximately ¥2.65 billion, representing a 24.59% increase compared to ¥2.13 billion in 2022[46]. - Net profit attributable to shareholders increased by 130.58% to approximately ¥416.12 million from ¥180.47 million in the previous year[46]. - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 141.52%, amounting to approximately ¥383.41 million compared to ¥158.75 million in 2022[46]. - The net cash flow from operating activities surged by 174.30% to approximately ¥634.45 million, up from ¥231.30 million in the previous year[46]. - Total assets as of the end of 2023 were approximately ¥7.11 billion, a 3.09% increase from ¥6.89 billion at the end of 2022[46]. - The net assets attributable to shareholders increased by 2.46% to approximately ¥5.65 billion from ¥5.51 billion in 2022[46]. - Total revenue for 2023 reached CNY 2,645,068,738.47, an increase of 25.11% compared to the previous year[79]. - The overall gross profit margin for the main business reached 70.46%, an increase of 1.51 percentage points from the previous year[104]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 10.00 per 10 shares, totaling CNY 166,833,930.00[9]. Research and Development - Research and development expenses accounted for 8.29% of operating revenue, a slight decrease of 0.26 percentage points from 8.55% in 2022[24]. - Research and development expenses amounted to CNY 220,098,318.01, a 20.81% increase from CNY 182,191,781.51 in the previous year, reflecting the company's commitment to innovation[75]. - The company has established an integrated R&D system across China, the US, the UK, France, and Israel, enhancing its technological capabilities and market competitiveness[64]. - The company is focusing on high-end implantable biomaterials, which require complex R&D and have a long development cycle[130]. - The company has several products in various stages of development, including new types of biological gels and cross-linked hyaluronic acid gels[132]. Market Expansion and Product Development - The company is actively expanding its product line in the medical aesthetics sector, including investments in RF and laser medical devices, as well as home-use instruments and botulinum toxin products[66]. - The company is focused on international expansion and has acquired several overseas companies to facilitate the transfer of advanced technologies and products to the domestic market[73]. - The company anticipates continued growth in the medical beauty market, projected to achieve a compound annual growth rate of 15%-20% over the next five years[94]. - The company is leveraging its multi-brand product line and cost advantages to adapt to the new marketing landscape post-volume procurement in the ophthalmology sector[143]. Sales and Revenue Breakdown - Revenue from ophthalmic products was CNY 928,214,432.86, a decrease of 20.57% year-on-year, with a gross margin of 59.11%[79]. - Revenue from medical beauty and wound care products increased by 41.27% to CNY 1,056,860,493.91, with a gross margin of 77.45%[79]. - Revenue from mainland China was CNY 2,191,972,736.84, up 28.20% year-on-year, with a gross margin of 73.65%[79]. - Direct sales accounted for CNY 1,321,405,596.97 in revenue, an increase of 28.49%, with a gross margin of 77.77%[79]. Operational Efficiency - The company has established a procurement center to enhance operational efficiency and reduce costs, focusing on centralized procurement of raw materials and equipment[162]. - The company has entered into significant procurement and sales contracts during the reporting period, enhancing its operational capabilities[82]. Future Outlook - The company’s future outlook includes continued investment in R&D and potential market expansion strategies[24]. - The company is exploring advanced technologies and products in ophthalmology, medical aesthetics, orthopedics, and surgery to ensure sustainable long-term development[147]. Corporate Governance - The company has no non-operating fund occupation by controlling shareholders or related parties[11]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team[8].

Financial Performance - The company recorded a total revenue of RMB 2,634.91 million for the year ended December 31, 2023, representing an increase of RMB 531.47 million or 25.27% compared to the previous year[2]. - Net profit attributable to shareholders was approximately RMB 416.12 million, reflecting a growth of 130.58% compared to the previous year, while the net profit excluding non-recurring items was RMB 383.41 million, up 141.52%[2]. - The gross profit for the year was RMB 1,853.51 million, compared to RMB 1,446.92 million in 2022, indicating a significant increase in profitability[3]. - The company reported a total comprehensive income of RMB 404.44 million for the year, significantly higher than RMB 100.70 million in 2022[4]. - The basic and diluted earnings per share for the year were RMB 2.44, compared to RMB 1.04 in the previous year, showcasing strong earnings growth[4]. - The total tax expense for the year 2023 amounted to RMB 95,991,000, an increase of 111.1% compared to RMB 45,395,000 in 2022[30]. Research and Development - Research and development expenses amounted to approximately RMB 220.10 million, an increase of RMB 37.91 million or 20.81% year-over-year, accounting for 8.35% of total revenue[2]. - The company is focusing on expanding its ophthalmic and aesthetic innovation product lines, with several key R&D projects progressing smoothly[48]. - The hydrophobic injection aspheric intraocular lens product has been approved for registration and market launch in June 2023, while other products are in various stages of clinical trials and registration[48]. - The company has initiated clinical trials for the innovative hydrophobic molded aspheric trifocal artificial lens in July 2023[56]. Dividends and Share Repurchase - The board proposed a final dividend of RMB 1.00 per share for the year ended December 31, 2023, compared to RMB 0.40 per share in 2022, and recommended a bonus issue of 4 new shares for every 10 existing shares[2]. - The total number of H-shares repurchased in 2023 was 3,872,400, with a total expenditure of HKD 166,589,234.00[89]. - The total number of A-shares repurchased in 2023 was 1,089,486, with a total expenditure of RMB 117,145,262.95[90]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 6,389.55 million, slightly up from RMB 6,381.12 million in the previous year[5]. - Current assets increased to RMB 3,750.14 million from RMB 3,532.12 million, indicating improved liquidity[5]. - The company’s total liabilities amounted to RMB 407.95 million as of December 31, 2023, compared to RMB 118.26 million in 2022[40]. - The current portion of total liabilities was RMB 216.63 million, while the non-current portion was RMB 191.32 million[40]. Revenue Breakdown - Revenue from mainland China was RMB 2,181,814 thousand, up 28.5% from RMB 1,699,078 thousand in 2022[22]. - The ophthalmology product line generated RMB 924.65 million in revenue, accounting for 35.10% of total revenue, with a year-on-year growth of 20.72%[47]. - The medical beauty and wound care product line reported revenue of RMB 1,052.80 million, representing 39.95% of total revenue, with a significant year-on-year growth of 41.44%[47]. - The orthopedic product line's revenue reached RMB 474.26 million, making up 18.00% of total revenue, with a year-on-year increase of 22.71%[47]. Market Position and Strategy - The company has been recognized as a high-tech enterprise, allowing a preferential tax rate of 15% for certain subsidiaries in 2023[6]. - The company aims to accelerate the localization of the ophthalmic industry in China and become a globally recognized comprehensive ophthalmic product manufacturer[50]. - The company has established exclusive distribution rights for high-end corneal reshaping lenses in mainland China, enhancing its market share and influence[56]. - The company plans to focus on four rapidly developing treatment areas: ophthalmology, medical aesthetics, wound care, and orthopedics, while enhancing research and development capabilities[69]. Compliance and Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[93]. - The audit committee reviewed the audited consolidated financial statements and annual results for the year ending December 31, 2023[94]. - The annual report containing all data required by the Hong Kong Listing Rules will be sent to shareholders and published on the relevant websites in due course[95].

Investment Rating - The report assigns a "Buy" rating for both A-shares and H-shares of the company, with a target price of 119.5 CNY for A-shares and 54.1 HKD for H-shares [2][11]. Core Views - The company has reported a strong growth in annual performance for 2023, with revenue expected to be in the range of 3.83 to 3.83 billion CNY, representing a year-on-year increase of 4-4.3 billion CNY [2][4]. - The net profit attributable to the parent company is projected to be 4.16 billion CNY, showing a year-on-year growth of 130.58% [2][4]. - The company has maintained stable operations, particularly in the aesthetic medicine segment, with significant sales performance in hyaluronic acid products [2][4]. - The company has developed a comprehensive product matrix covering four major business areas, including hyaluronic acid fillers and laser equipment, with ongoing research and development efforts [2][4]. Financial Summary - Revenue for 2023 is expected to reach 2,654 million CNY, with a growth rate of 24.6% compared to the previous year [2][7]. - The net profit for 2023 is projected at 416 million CNY, reflecting a growth rate of 130.3% [2][7]. - Earnings per share (EPS) for 2023 is estimated to be 2.42 CNY, with a corresponding price-to-earnings (P/E) ratio of 43.23 [2][7]. - The company’s EBITDA is expected to be 594 million CNY for 2023, indicating a significant increase from previous years [2][7].

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海昊海生物科技股份有限公司 2021 年 A 股限制性股票激励计划预留授予部分第一个归属 期归属条件成就及作废部分已授予但尚未归属的限制性股 票相关事项之 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海昊海生物科技股份有限公司 2021 年 A 股限制性股票激励计划预留授予部分第一个归属期归 属条件成就及作废部分已授予但尚未归属的限制性股票相关事 项之法律意见书 致：上海昊海生物科技股份有限公司 第一部分 引言 上海市锦天城律师事务所（以下简称"本所"）接受上海昊海生物科技股份 有限公司（以下简称"昊海生科"或"公司"）的委托，指派周健律师和尹英爱 律师作为公司特聘专项法律顾问，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司股权激励管理办法》《上海证券交易所科创板股票上市 规则》《科创板上市公司自律监管指南第 4 号——股权激励信息披露》及其 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2023年11月6日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 06826 | 說明 | H 股 | | | | | | 發行股份 | (註6及7) | 股份數目 | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月3日 | | 32,895,100 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 20,700 ...